Table 1.

Baseline Sample Characteristics of FDA Approved Targeted Multi-Indication Cancer Drugs

	No	(%)
FDA Approval Sequence
Initial Indication	25	(25.0%)
Supplementary Indication	75	(75.0%)
Line of Treatment
1st line	38	(38.0%)
2nd, 3rd, 4th line	62	(62.0%)
Treatment Type
Monotherapy	82	(82.0%)
Combination	18	(18.0%)
Multi-Indication Drug Type
Across Therapeutic Areas	20	(20.0%)
Across Disease Areas	57	(57.0%)
Across Lines of Therapy	23	(23.0%)
Total No. of Indications	100	(100%)

FDA US Food and Drug Administration, EMA European Medicines Agency, HC Health Canada, TGA Therapeutics Goods Administration